Production (Stage)
Orchestra BioMed Holdings, Inc.
OBIO
$2.72
-$0.01-0.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.00% | -3.44% | 135.56% | -14.97% | -46.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.00% | -3.44% | 135.56% | -14.97% | -46.74% |
| Cost of Revenue | 29.41% | 23.40% | 65.85% | -18.52% | -22.73% |
| Gross Profit | 40.61% | -9.30% | 143.12% | -14.75% | -47.68% |
| SG&A Expenses | 6.21% | 41.00% | -10.69% | 21.61% | 33.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.55% | 32.86% | 15.97% | 27.15% | 18.36% |
| Operating Income | -31.19% | -33.62% | -12.52% | -30.13% | -24.93% |
| Income Before Tax | -39.31% | -26.03% | -15.85% | -32.66% | -23.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.31% | -26.03% | -15.85% | -32.66% | -23.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.31% | -26.03% | -15.85% | -32.66% | -23.06% |
| EBIT | -31.19% | -33.62% | -12.52% | -30.13% | -24.93% |
| EBITDA | -31.28% | -33.72% | -12.54% | -30.29% | -25.06% |
| EPS Basic | -30.35% | -16.34% | -8.52% | -28.28% | 4.93% |
| Normalized Basic EPS | -30.80% | -31.14% | -6.22% | -28.45% | 5.37% |
| EPS Diluted | -29.08% | -16.34% | -8.52% | -28.28% | 3.99% |
| Normalized Diluted EPS | -30.80% | -31.14% | -6.22% | -28.45% | 5.37% |
| Average Basic Shares Outstanding | 6.87% | 8.32% | 6.75% | 3.43% | 29.43% |
| Average Diluted Shares Outstanding | 6.87% | 8.32% | 6.75% | 3.43% | 29.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |